Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S R Hayman

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Leukemia|January 19, 2007
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyA K Stewart, P L Bergsagel, P R Greipp, et al.
Bone Marrow Transplantation|May 4, 2010
Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilizationH V Naina, R K Pruthi, D J Inwards, et al.
Blood Cancer Journal|March 12, 2016
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Bone Marrow Transplantation|April 12, 2016
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapyW I Gonsalves, S V Rajkumar, M A Gertz, et al.
Leukemia|December 17, 2015
Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatmentT V Kourelis, F K Buadi, M A Gertz, et al.
Blood Cancer Journal|September 2, 2017
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Bone Marrow Transplantation|September 5, 2017
A phase 1 trial of <sup>90</sup>Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myelomaA Dispenzieri, A D'Souza, M A Gertz, et al.
Journal of Internal Medicine|April 26, 2017
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosisE Muchtar, D S Dean, A Dispenzieri, et al.
Leukemia|September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)M Q Lacy, S R Hayman, M A Gertz, et al.
Leukemia|December 2, 2016
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment categoryE Muchtar, A Dispenzieri, S K Kumar, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Leukemia|January 19, 2007
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyA K Stewart, P L Bergsagel, P R Greipp, et al.
Bone Marrow Transplantation|May 4, 2010
Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilizationH V Naina, R K Pruthi, D J Inwards, et al.
Blood Cancer Journal|March 12, 2016
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Bone Marrow Transplantation|April 12, 2016
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapyW I Gonsalves, S V Rajkumar, M A Gertz, et al.
Leukemia|December 17, 2015
Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatmentT V Kourelis, F K Buadi, M A Gertz, et al.
Blood Cancer Journal|September 2, 2017
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Bone Marrow Transplantation|September 5, 2017
A phase 1 trial of <sup>90</sup>Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myelomaA Dispenzieri, A D'Souza, M A Gertz, et al.
Journal of Internal Medicine|April 26, 2017
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosisE Muchtar, D S Dean, A Dispenzieri, et al.
Leukemia|September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)M Q Lacy, S R Hayman, M A Gertz, et al.
Leukemia|December 2, 2016
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment categoryE Muchtar, A Dispenzieri, S K Kumar, et al.
Pageof 6